A Dose-Response Safety Study of ENX-102 in Patients With GAD
Status:
COMPLETED
Trial end date:
2025-06-23
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD